Funding & Awards

Beker Multiple Sclerosis Research Laboratory

Fund/Award	Name	Date
NINDS R01 NS085103-01	John (PI)	9/1/14-8/31/19
Kruppel-like factor-6 signaling in myelin formation and repair. The goals of this study are to define effects of the GC box transcription factor Krüppel-like factor-6 on oligodendrocyte differentiation, and myelin formation. This work aims to identify novel avenues to promote remyelination in demyelinating conditions such as MS.
National MS Society RG RG-1501-02870	John (PI)	10/1/15-9/30/18
Reactive astrogliosis regulates blood-brain barrier permeability. The goals of this study are todefine the mechanism underlying effects of VEGF-A on CNS endothelial permeability, determine the roles of HIF-VEGF and disruption of CLN-5 and OCLN in BBB breakdown in vivo and define the contributions of HIF-1a and VEGF-A to BBB disruption and symptom production in EAE.
National MS Society RG 5024	John (PI)	10/1/14-8/31/17
Kruppel-like factor-6 signaling in myelin formation and repair. The goals of this study are to define effects of the transcription factor Krüppel-like factor-6 on oligodendrocyte differentiation, and myelination. This award overlaps with NINDS R01 NS085103, above. Overlap has been resolved.
NINDS R01 NS062703-06	John (PI)	9/1/10-8/31/19
Reactive astrogliosis regulates blood-brain barrier permeability The goals of this study are to define the mechanism underlying effects of VEGF-A on CNS endothelial permeability, determine the roles of HIF-VEGF and disruption of CLN-5 and OCLN in BBB breakdown in vivo and define the contributions of HIF-1a and VEGF-A to BBB disruption and symptom production in EAE. This work aims to identify a novel therapeutic avenue for inflammatory CNS disease. It has recently been renewed through 2019.
Sanofi-Genzyme Corporation Award	John (PI)	1/1/15-12/31/16
Teriflunomide – relevance to oligodendrocyte protection and myelin formation Teriflunomide is a compound FDA-approved for use as a therapeutic in relapsing-remitting MS. The goals of this study are to identify roles of teriflunomide in oligodendrocyte differentiation and myelin formation. This work aims to identify new avenues to promote remyelination and return of function in MS and related conditions.
TEVA Pharmaceuticals Research Award	John/Brück (PIs)	1/1/16-12/31/18
Understanding the molecular mechanism of action of Laquinimod. This study examines the detailed molecular mechanism of action of Laquinimod, an immunomodulator of innate immune responses that exerts is strongest actions on glial inflammation within the CNS.
Beker Foundation Award	John (PI)	7/1/2011-6/30/21
Beker Postdoctoral Fellowship Program. This award was made by a private foundation for the establishment of a postdoctoral fellowship position in MS research in the John laboratory.
Muzio Foundation Award	John (PI)	10/1/15-9/30/20
This award was made by a private foundation for the establishment of a research program into therapeutic discovery for neuromyelitis optica in the John laboratory.